Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical …

Background The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting
β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head …

In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with
chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out …

Background Many patients with asthma or chronic obstructive pulmonary disease (COPD)
routinely receive a combination of an inhaled bronchodilator and anti-inflammatory …

… Requires an inhalation flow rate of only ∼27 L·min−1 for actuation, which can be generated
by patients with COPD (no coordination needed). Elderly patients and those with arthritis …

… FEV 1 (L) increased as compared to baseline by an average of 21.5% (P = 0.0025) for the
1200 µg dose, 16.2% (P = 0.02) for the 600 µg dose, and 9.2% (P = NS) for the 300 µg dose …

Asthma is associated with several comorbidities but the magnitude of the association has
not been clearly defined. We aimed to examine the relationship between asthma and …

Tumor necrosis factor (TNF)-α, a pleiotropic cytokine that exerts a variety of effects, such as
growth promotion, growth inhibition, angiogenesis, cytotoxicity, inflammation, and …

Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …

Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …